Background pattern of a brain with neural connections

Team PPMI

Identifying biological markers of Parkinson’s disease risk, onset and progression

Team PPMI provides CRN researchers with a direct connection to the Parkinson’s Progression Marker Initiative, a landmark observational study that was launched in 2010 with the goal of identifying biological markers of Parkinson’s disease risk, onset and progression through longitudinal clinical, imaging and biosample analyses.

A critical component of PPMI is the standardized, longitudinal collection of biospecimens along with clinical and imaging data. These include plasma, serum, blood, cerebrospinal fluid (CSF), DNA and RNA, peripheral mononuclear blood cells (PBMCs) and iPSCs from a subset of individuals enrolled in the study.

PPMI offers researchers access to collected data, biosamples, and iPSCs.

Learn More About PPMI
Ken Marek

Ken Marek

Lead PI (Core Leadership)

Kalpana Merchant

Kalpana Merchant

Co-PI (Core Leadership)

Brit Mollenhauer

Brit Mollenhauer

Co-PI (Core Leadership)

Kathleen Poston

Kathleen Poston

Co-PI (Core Leadership)

Tatyana Simuni

Tatyana Simuni

Co-PI (Core Leadership)

Alyssa O'Grady

Alyssa O'Grady

Project Manager

Project Highlights

View All

Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression

Challenge: Identifying a meaningful progression metric for Parkinson's disease (PD) that reflects heterogeneity remains a challenge. Objective: To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones. Methods: Using data from the Parkinson's Progression Markers Initiative (PPMI) de novo PD cohort, we monitored...

In the News

View All
next resource team:

CRN Cloud→